Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.37 |
| ▸ | AXL | P30530 | 3/20 | 0.35 |
| ▸ | MERTK | Q12866 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365553 | 0.85 | ALDH1A1 (0.43) | ALDH1A1PIK3CDACVRL1AXLMERTK | |
| SCHEMBL64680 | 0.83 | ALDH1A1 (0.42) | ALDH1A1PIK3CDACVRL1AXLMERTK | |
| SCHEMBL19280465 | 0.81 | PIK3CD (0.35) | ALDH1A1PIK3CDACVRL1RETKDR | |
| SCHEMBL19698013 | 0.81 | PIK3CD (0.35) | ALDH1A1PIK3CDACVRL1RETKDR | |
| SCHEMBL24393051 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KDR | |
| SCHEMBL65572 | 0.79 | ACVRL1 (0.45) | PIK3CDACVRL1AXLMERTK | |
| SCHEMBL26505471 | 0.79 | PIK3CD (0.34) | ALDH1A1PIK3CDACVRL1RETKDR | |
| SCHEMBL26690322 | 0.79 | ACVRL1 (0.52) | PIK3CDACVRL1RETKDR | |
| SCHEMBL14647493 | 0.79 | ACVRL1 (0.39) | ALDH1A1PIK3CDACVRL1AXLMERTK | |
| SCHEMBL18374578 | 0.79 | ALDH1A1 (0.39) | ALDH1A1PIK3CDACVRL1AXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10023576-B2 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2548877-A1 | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors | MSD Oss B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
| US-8143393-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-8129379-B2 | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER HEALTHCARE LLC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | ALDH1A1 3131/4885PIK3CD 14/4885ACVRL1 2053/4885 |
| US-20100179125-A1 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | CDK4, CDKL4, MKI67 | ALDH1A1 3325/4885PIK3CD 529/4885ACVRL1 941/4885 |
| US-20100063038-A1 | Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | CDK4, CDKL4, MKI67 | ALDH1A1 3327/4885PIK3CD 608/4885ACVRL1 963/4885 |
| US-10023576-B2 | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | PIK3R3, PIK3R5, PIK3R1 | ALDH1A1 4203/4885PIK3CD 6/4885ACVRL1 3003/4885 |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | PIK3R3, PIK3R5, PIK3R1 | ALDH1A1 4203/4885PIK3CD 6/4885ACVRL1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.